The seven-row TL;DR
For each dimension where one drug clearly wins, we name the winner. Where the answer is "depends on your situation," the verdict text below the table explains why.
| Dimension | What the data says | Winner |
|---|---|---|
| Active ingredient | Tirzepatide in both | Tie |
| FDA approval as drug product | Zepbound yes; compounded no | Zepbound |
| Cash-pay cost | $199-$349/mo (compounded) vs $349-$549/mo (LillyDirect) | Compounded |
| Insurance coverage | Zepbound with PA; compounded never covered | Zepbound |
| Supply continuity in 2025-2026 | Zepbound stable; compounded tirzepatide actively litigated by Lilly | Zepbound |
| Active enforcement risk | Lilly lawsuits coordinated against 503A pharmacies | Zepbound |
| Prescriber access | Most weight loss telehealth programs prescribe Zepbound; fewer offer compounded tirzepatide in 2026 than in 2024 | Zepbound |
Verdict
Of all the GLP-1 compounded-vs-branded comparisons in 2026, this is the one where we lean hardest toward branded. Lilly has actively litigated compounded tirzepatide through 2025-2026; several 503A pharmacies have been enjoined or paused programs. Mid-treatment supply disruption is a real risk. If you cannot access Zepbound through insurance and LillyDirect's $349 is out of reach, compounded tirzepatide via a still-active program is defensible — but you should have an explicit Plan B that doesn't depend on continued compounded supply. Some patients in this situation reasonably switch to compounded semaglutide instead, accepting lower expected weight loss for more stable supply.
Trial efficacy compared
The headline numbers are not from the same study, so direct comparison is approximate. The 2024 SURMOUNT-5 trial directly compared tirzepatide to semaglutide and found tirzepatide produced greater weight loss across all dose comparisons, validating the cross-trial signal.
| Compounded tirzepatide | Zepbound | |
|---|---|---|
| Registration trial | SURMOUNT-1 (parent molecule, Zepbound) (NEJM, 2022) | SURMOUNT-1 (NEJM, 2022) |
| Duration | 72 weeks | 72 weeks |
| Mean weight loss (max dose) | 20.9% | 20.9% |
| Effect vs placebo | 17.8 pp | 17.8 pp |
| Patients losing ≥5% | 91.0% | 91.0% |
| Patients losing ≥15% | 56.7% | 56.7% |
2026 cash-pay cost compared
Both manufacturers run direct-to-consumer cash channels (NovoCare for Compounded tirzepatide, LillyDirect for Zepbound) which are dramatically cheaper than the retail pharmacy cash price. Telehealth programs add a membership fee on top of medication cost.
| Channel | Compounded tirzepatide | Zepbound |
|---|---|---|
| Retail cash | Not sold at retail; cash-pay through telehealth programs only | $1,099/mo |
| Manufacturer DTC | $199-$349/mo via telehealth programs where supply remains available | $349-$549/mo via LillyDirect (vials cheaper than pens) |
| With insurance + PA | Not covered. Compounded medications are not eligible for insurance reimbursement. | $25-$50/mo with prior authorization |
| Compounded | Cash-pay only. Supply has narrowed considerably in 2025-2026 as Lilly has filed coordinated lawsuits against compounded tirzepatide pharmacies. | $199-$349/mo via 503A pharmacies (regulatory exposure) |
When to choose Compounded tirzepatide
Choose compounded tirzepatide if: (1) you have no insurance and LillyDirect's $349 is out of reach; (2) you specifically need tirzepatide's mechanism (you've tried semaglutide and it didn't reach your goal weight); (3) you've selected a program with active 503A supply and transparent continuity planning; (4) you understand the supply risk and have a Plan B (typically Zepbound with insurance PA, or compounded semaglutide).
When to choose Zepbound
Choose Zepbound if: (1) your insurance covers it; (2) LillyDirect's $349-$549 is within budget; (3) you want supply continuity that doesn't depend on the outcome of active Lilly litigation; (4) you have obstructive sleep apnea (Zepbound has the OSA indication, which compounded does not carry as a labeled indication).
Programs that prescribe each
Top Compounded tirzepatide programs
Top Zepbound programs
FAQ
Is compounded tirzepatide the same as Zepbound?
Why is Lilly suing compounded tirzepatide pharmacies?
Will compounded tirzepatide still be available next year?
If my supply is cut off mid-treatment, what happens?
Should I just choose compounded semaglutide instead?
Read the full drug profiles
Editorial disclosure
GLP Chart is an editorial comparison site. We do not dispense, prescribe, or fulfill medications. Trial data is from the cited NEJM publications. Pricing reflects publicly verified rates as of 12 May 2026. Talk to a licensed clinician about which medication is appropriate for you.